Cognex saves $9,200 in medical costs compared to no treatment -- Technology Assessment Group.
WARNER-LAMBERT COGNEX SAVES $9,200 IN TOTAL COSTS v. NO TREATMENT, according to an economic impact analysis performed for the manufacturer by San Francisco-based Technology Assessment Group. The study was presented by TAG's Curtis Henke at the Association for Pharmacoeconomics & Outcomes Research meeting on May 13 in Philadelphia.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth